Pacific Edge in holding mode as US Medicare decision nears

Pacific Edge in holding mode as US Medicare decision nears
Total laboratory use of Pacific Edge's Cxbladder tests in the US rose in the 2024 financial year but the growth rate slowed in the second half as the company reduced its sales team. (Image: Thinkstock)
Greg Hurrell
Pacific Edge says the 2024 finance year has been one of two halves, as it quickly switched from growth to capital preservation.That sudden change of focus came from a major setback with the possible loss of access to the US Medicare system which has been its largest customer.The company reported a loss of $29.5 million for the March 31 financial year, 9.5% bigger than 2023’s net loss, amid that slowing growth.MedicareThe company said it was prepared for all outcomes as it waited to see whether it would hang on to its Medicare deal, which...

More Markets

Calm before the storm: NZ sharemarket up 0.5%
Finance Market close

Calm before the storm: NZ sharemarket up 0.5%

'Markets are distracted', said ForBarr's Peter Sigley.

Gregor Thompson 05 Nov 2024
KPMG to lay off 4% of its US audit workforce
Finance

KPMG to lay off 4% of its US audit workforce

About 330 people in the US audit business to lose their jobs.

Carbon Catchup: Who's up, who's down?
Finance

Carbon Catchup: Who's up, who's down?

12 companies from the NZX50 increased their direct emissions compared to last year.

Murray Jones 05 Nov 2024
NZ sharemarket up slightly ahead of ‘wait-and-see' US election
Markets Market Close

NZ sharemarket up slightly ahead of ‘wait-and-see' US election

The S&P/NZX 50 Index closed at 12,590.6, up 31.32 points or 0.25%.

Gregor Thompson 04 Nov 2024